ASMB Assembly Biosciences, Inc.
USHealthcareAs of 2026-07-09 16:00
Why ASMB matters now
Assembly Biosciences, Inc. (ASMB) is a US stock in Healthcare. The latest InvestLog snapshot shows $27.87 with -2.99% on the session and $442.9M in market capitalization; recent performance reads 1-month -7.84% and YTD -28.14%.
The latest financial table shown here is Q1 2026, with revenue of $8.2M, net income of $-9.1M, and EPS of $-0.54. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -10.3%.
The latest indexable market news headline is "Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead" from MarketBeat.
Additional event context on this page matters because analyst consensus is Buy with a median target of $45.00; recent insider activity includes Bjorkquist Jeanette M filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.08
P/S
5.46
EV/EBITDA
-57.47
DCF Value
$-62.25
FCF Yield
-10.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.2%
Operating Margin
-19.1%
Net Margin
-9.0%
ROE
-4.2%
ROA
-2.7%
ROIC
-6.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.2M | $-9.1M | $-0.54 |
| Q4 2025 | $42.5M | $22.1M | $2.49 |
| FY 2025 | $72.3M | $-6.1M | $-0.55 |
| Q3 2025 | $10.8M | $-9.2M | $-1.20 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$45.00
Target (Median)
$45.00
Target Range
$45.00 - $45.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.08
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.